**For Available Speaker Slots**
eurobiosimilars@conferencesmail.org
## Program at a Glance

### Day 1

<table>
<thead>
<tr>
<th>Time</th>
<th>General Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-09.00</td>
<td><strong>Inaugural Address</strong></td>
</tr>
<tr>
<td>09.00-09.15</td>
<td><strong>Keynote/Plenary Talk 1</strong></td>
</tr>
<tr>
<td>09.15-09.45</td>
<td><strong>Keynote/Plenary Talk 2</strong></td>
</tr>
<tr>
<td>09.45-10.15</td>
<td><strong>Keynote/Plenary Talk 3</strong></td>
</tr>
<tr>
<td>10.15-10.45</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Panel Discussions/Group Photo</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Coffee/Tea Break 10.45-11.00 (Networking)</strong></td>
</tr>
<tr>
<td>11.00-12.40</td>
<td><strong>5 Speakers (20 Mins Each)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Lunch Break 12.40-13.30</strong></td>
</tr>
<tr>
<td>13.30-15.30</td>
<td><strong>6 Speakers (20 Mins Each)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Coffee/Tea Break 15.30-15.45 (Networking)</strong></td>
</tr>
<tr>
<td>15.45-17.25</td>
<td><strong>5 Speakers (20 Mins Each)</strong></td>
</tr>
</tbody>
</table>

### Day 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-10.40</td>
<td><strong>5 Speakers (20 Mins Each)</strong></td>
<td><strong>5 Speakers (20 Mins Each)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Coffee/Tea Break 10.40-10.55 (Networking)</strong></td>
<td></td>
</tr>
<tr>
<td>10.55-12.35</td>
<td><strong>5 Speakers (20 Mins Each)</strong></td>
<td><strong>5 Speakers (20 Mins Each)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Lunch Break 12.35-13.25</strong></td>
<td><strong>5 Speakers (20 Mins Each)</strong></td>
</tr>
<tr>
<td>13.25-15.05</td>
<td><strong>5 Speakers (20 Mins Each)</strong></td>
<td><strong>5 Speakers (20 Mins Each)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Poster Sessions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Coffee/Tea Break 15.05-15.20 (Networking)</strong></td>
<td></td>
</tr>
<tr>
<td>15.20-17.00</td>
<td><strong>5 Speakers (20 Mins Each)</strong></td>
<td><strong>5 Speakers (20 Mins Each)</strong></td>
</tr>
</tbody>
</table>

**For More Details, Visit:** [http://biosimilars-biologics.pharmaceuticalconferences.com/europe/](http://biosimilars-biologics.pharmaceuticalconferences.com/europe/)
### Featured Presentations

#### Tentative Scientific Program
Speaker opportunities available, submit your abstract online @

#### Speakers

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christoph Volpers</td>
<td>Michalski Hüttermann &amp; Partner, Germany</td>
<td>Intellectual Property and Regulatory Interplay in Biosimilars</td>
</tr>
<tr>
<td>Ulrich Storz</td>
<td>Michalski Hüttermann &amp; Partner, Germany</td>
<td>How AbbVie tries to fend off world’s blockbuster No 1 from generic competition</td>
</tr>
<tr>
<td>Stanley Seung Suh Hong</td>
<td>Celltrion Healthcare Co. Ltd., South Korea</td>
<td>Evidence-based approach of CT-P13 to meet the expectations of different stakeholders</td>
</tr>
<tr>
<td>Ulrike Konrad</td>
<td>Karl Ruprecht Universität, Germany</td>
<td>CMC Considerations for Biosimilar Drug Development</td>
</tr>
<tr>
<td>Arthur G. Cook</td>
<td>ZS Associates, USA</td>
<td>The Commercial Landscape for Biosimilars: Planning in an Uncertain Environment</td>
</tr>
<tr>
<td>Tim Demuth</td>
<td>Sandoz, Germany</td>
<td>Development of etanercept biosimilar Erelzi</td>
</tr>
<tr>
<td>Andras Guttman</td>
<td>University of Pannonia, USA</td>
<td>Multilevel characterization of biosimilars by CE-LIF and CE-MS</td>
</tr>
<tr>
<td>Rosa Helena Bustos</td>
<td>Universidad de La Sabana, Colombia</td>
<td>Search for unknown immunogenicity: An overview</td>
</tr>
<tr>
<td>Dina E Abo Elezz</td>
<td>Pharos University, Egypt</td>
<td>Development and <em>in-vivo</em> evaluation of ofloxacin gastro-retentive drug delivery system</td>
</tr>
</tbody>
</table>

**Note:** Program is subject to change with final allotment of the speaker slots.
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Institution</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Özgenur Dokur</strong>, Ege University Turkey</td>
<td></td>
<td>Investigation of chemoprevention properties of <em>Halopteris scoparia</em> brown algae by using <em>in vivo</em> bioluminescent imaging</td>
</tr>
<tr>
<td><strong>Rodica Olteanu</strong>, Colentina Clinical Hospital, Romania</td>
<td></td>
<td>Inflectra—our experience on immunogenicity (case series)</td>
</tr>
<tr>
<td><strong>Carlos Daniel Zapata</strong>, University of La Sabana, Colombia</td>
<td></td>
<td>Development of a methodology for the evaluation of tumor necrosis factor antibody (anti-TNF-alpha) in patients with treatment of biological products through the use of nano biosensors</td>
</tr>
<tr>
<td><strong>Ravish Patel</strong>, EPR Centre for Cancer Research &amp; Bioinformatics Pvt. Ltd., India</td>
<td></td>
<td>Physicochemical and functional characterization of a bio-similar Bevacizumab</td>
</tr>
<tr>
<td><strong>Christian B Fulda</strong>, Jones Day, Germany</td>
<td></td>
<td>Consequences of Brexit on biosimilars</td>
</tr>
<tr>
<td><strong>Kamali Chance</strong>, QuintilesIMS, USA</td>
<td></td>
<td>FDA/EMA current thinking on totality of evidence for development of biosimilars</td>
</tr>
<tr>
<td><strong>Armenia Nazar</strong>, University of Andalas, Indonesia</td>
<td></td>
<td>Study of liver toxicity and its reversibility of <em>Cassytha filiformis</em> defatted ethanolic extract on mice</td>
</tr>
<tr>
<td><strong>Asif Mahmood</strong>, Pfizer, United States</td>
<td></td>
<td>Biosimilars: Challenges in safety and risk management</td>
</tr>
<tr>
<td><strong>M A Attia</strong>, Assiut University, Egypt</td>
<td></td>
<td>Hydrophobic ion-pairing of low molecular weight heparin with cationic amphiphiles</td>
</tr>
</tbody>
</table>

**NOTE:** Program is subject to change with final allotment of the speaker slots
7th European Biosimilars Congress
May 15-16, 2017 Munich, Germany

Media Partners & Exhibitors

http://biosimilars-biologics.pharmaceuticalconferences.com/europe/
7th European Biosimilars Congress
May 15-16, 2017   Munich, Germany

Top Participating Organisations

http://biosimilars-biologics.pharmaceuticalconferences.com/europe/
Previous Speakers

Patrick Lucy
Pfenex Inc., USA

Alex Brill
Matrix Global Advisors, USA

Jill A. Myers
Momenta Pharmaceuticals, USA

Jenny Chen
Wolf, Greenfield & Sacks, P.C., USA

Milind Antani
Nishith Desai Associates, India

William A. Sarraille
Sidley Austin LLP, USA

Timothy J Shea
Sterne, Kessler, Goldstein & Fox PLLC, USA

Denise M Kettelberger
Sunstein Kann Murphy & Timbers LLP, USA

Gregory J Glover
Pharmaceutical Law Group PC, USA

Christopher J Leintz
Pfizer, Inc, USA

Subir Roy
DGM- Marketing & Medical at Zydus Cadila, India

Sunit Maity
Theramyt Novobiologics Pvt. Ltd., India

Mark A. Emalfarb
Dyadic International, Inc., USA

Vivek Kumar Morya
Inha University, Republic of Korea, South Korea

Abdel Halim Harrath
King Saud University, Saudi Arabia

Neil Schauer
Avaxis Biologics, USA

http://biosimilars-biologics.pharmaceuticalconferences.com/europe/
Previous Speakers

Sarfaraz K. Niazi
TheraProteins, USA

Angela Furlanetto
Dimock Straiton LLP
Canada

Ronald A Rader
Biotechnology Information Institute, USA

Raymond A Huml
Quintiles, Inc., USA

James Harris III
Healthcare Economics LLC, USA

Lisa Mueller
Michael Best & Friedrich LLP, USA

Raj Dave
Pillsbury Winthrop Shaw Pittman, LLP, USA

Kerisha A. Bowen
Dentons US LLC, USA

Abe Hershkovitz
Hershkovitz & Associates, PLLC, USA

Nigel J Rulewski
Quintiles, Inc., USA

András Guttman
University of Pannonia, Hungary SCIEX, USA

Sumant Chaubey
Bills Biotech, India

Andreu Soldevila
CEO LeanBioPro
Spain

Tom Carver
Wragge Lawrence Graham & Co, UK

Christoph Volpers
Senior Patent Consultant at Michalski & Hüttermann, Germany

Wolfgang A. Rehmann
Taylor Wessing Germany

http://biosimilars-biologics.pharmaceuticalconferences.com/europe/
Previous Speakers

Candida Fratazzi  
BBCR Consulting, USA

Krishna Menon  
Cellceutix Corporation, USA

Daniel Galbraith  
BioOutsource Ltd, UK

Siddhartha Roy  
CSIR - Indian Institute of Chemical Biology, India

Noelle Sunstrom  
Neuclone PTY LTD Australia

Dipti Gulati  
PJI Biotech, USA

Alexander Pitters  
Kaiser Optical Systems France

Laszlo Endrenyi  
University of Toronto Canada

Christina Vessely  
Biologics Consulting, USA

Ruideger Janwosky  
Cinfa Biotech GmbH Germany

Christelle Dagoneau  
Catalent Biologics USA

Aparna Kasinath  
Syngene International India

http://biosimilars-biologics.pharmaceuticalconferences.com/europe/
Opening Ceremony

Keynote Forum

Introduction

Title: Biosimilars: Latin America’s Coming On Board: Regulatory Approval and Market Access
Marlene Llópiz-Avilés, Association of Medical Specialists in the Pharmaceutical Industry, Mexico

Title: The Commercial Landscape for Biosimilars: Planning in an Uncertain Environment
Arthur G Cook, ZS Associates, USA

Title: Impact of Biosimilars on Patent Portfolio Development and Management
Kristin A. Connarn, McDermott Will & Emery, USA

Title: Biosimilars in treatment of multiple sclerosis in Iran
Hossein Pakdaman, Shahid Beheshti University of Medical Sciences, Iran

Title: Systematic Shortlisting of Candidate Molecules and Biosimilar/Biobetter Product Development: An Undergraduate Research Effort
Balram Pani, Bhaskaracharya College of Applied Sciences -University of Delhi, India

Title: Emerging biosimilars in the USA – quo vadis
Melissa Law, Technology Catalysts International, USA

Day 2 October 20, 2016

Keynote Forum

Title: Use of Biophysical Techniques for the Analysis of Biosimilars
Mario DiPaola, Blue Stream Laboratories, Inc, USA

Title: Scientific Factors in Biosimilar Product Development
Laszlo Endrenyi, University of Toronto, Canada

Title: Biosimilars Regulations: Updates from Canada
Oxana Iliach, Quintiles, Canada

Title: Brexit and Biosimilars
Dipti Gulati, PJI Biotech, USA

Title: Evolution of Structure-Function paradigm in Biopharmaceutics based on Global Regulatory Needs
Dinesh Palanivelu, Biocon Research Centre, Bangalore, India

Title: Using IPRs In the Biosimilars Context
Laura Burson, Sheppard, Mullin, Richter & Hampton LLP, USA

Title: nSMOL-Development of novel LCMS bioanalytical approach by Fab-selective quantitation of monoclonal antibodies using nano-surface and molecular orientation limited proteolysis
Takashi Shimada, SHIMADZU Corporation, Japan

Day 3 October 21, 2016

Networking Refreshments
Day 1 June 27, 2016

Keynote Forum

Title: Interchangeability of biological drug products
Laszlo Endrenyi, University of Toronto, Canada

Title: Evaluating immunogenicity biosimilars
Candida Fratazzi, BBCR Consulting, USA

Title: FDA/EMA Current thinking on totality of evidence for biosimilar approvals
Kamali Chance, Quintiles Inc., USA

Title: Supporting biosimilar clinical trials in the UK
Sarah Cooper, National Health Service, UK

Title: The emergence of orphan Biosimilars
Triona Bolger, Navigant Consulting, Inc, UK

Title: The importance of IP protection and SPCs for biologics and biosimilar products
Luder Behrens, Boehmert & Boehmert, Germany

Title: An update on the legal landscape for biosimilars in the USA
Paul A Calvo, Sterne, Kessler, Goldstein & Fox, USA

Title: Intellectual Property Issues in global biosimilar programs
Christoph Volpers, Michalski Hütermann & Partner, Germany

Title: Dosing, double patenting and the US biosimilars landscape
Nabeela Rasheed, McAndrews, Held & Malloy, Ltd, USA

Day 2 June 28, 2016

Keynote Forum

Title: Strategies for biosimilars development
Andreu Soldevila, LeanBio Pro, Spain

Establishing “Finger-print like” biosimilarity—Critical characterization steps for biosimilar assessment.
Fiona M Greer, SGS Life Sciences, Switzerland

Title: Biosimilar development cost: Role of analytics
Dipti Gulati, PJI Biotech, USA

Title: Pharmacovigilance in cancer medicine
Luis H Camacho, Center for Oncology and Blood Disorders, Houston, USA

Title: Process Raman Spectroscopy for in-Line monitoring of mammalian cell cultures in real time
Alexander Pitters, Kaiser Optical Systems, SARL, France

Title: Analytical assessment of biosimilarity – Considerations in study design
Christina Vessely, Biologics Consulting, USA

Title: Overcoming the challenges of biosimilar development as a mid-size player
Ruediger Jankowsky, Cinfa Biotech, Germany

Title: Recommendations from the AAPS LBABFG Biosimilars Action Program Committee for the validation of pharmacokinetic and immunogenicity assays in support of Biosimilar drug development
Aparna Kasinath, Syngene International Limited, India

Title: Impact on technology integration on better and faster Biosimilars pipeline
Christelle Dagoneau, Catalent Biologics, USA

Title: Biosimilar Globalization— A silver lining in untested waters
Candida Fratazzi, BBCR Consulting, USA

Title: From neuronal networks to neuromodulation with biosimilars
Luis Ulloa, Rutgers-New Jersey Medical School, USA

Title: High throughput assays for the determination of the potency and comparability of Biosimilars and innovator products
Michael G Tovey, INSERM, France

Title: Growth potential of Biosimilar products in Bangladesh
Md. Abu Zafar Sadek, Renata Ltd., Bangladesh
Day 1   October 26, 2015

**Keynote Forum**

<table>
<thead>
<tr>
<th>William A Sarraille</th>
<th>William A Sarraille, Sidley Austin LLP, USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Brill</td>
<td>Alex Brill, Matrix Global Advisors, USA</td>
</tr>
<tr>
<td>Jill A Myers</td>
<td>Jill A Myers, Momenta Pharmaceuticals, USA</td>
</tr>
<tr>
<td>Y Jenny Chen</td>
<td>Y Jenny Chen, Wolf Greenfield &amp; Sacks, PC, USA</td>
</tr>
<tr>
<td>Milind Antani</td>
<td>Milind Antani, Nishith Desai Associates, India</td>
</tr>
<tr>
<td>Timothy J Shea</td>
<td>Timothy J Shea, Sterne Kessler Goldstein &amp; Fox PLLC, USA</td>
</tr>
<tr>
<td>Gary C Cupit</td>
<td>Gary C Cupit, Somnus Therapeutics, USA</td>
</tr>
<tr>
<td>Ronald A Rader</td>
<td>Ronald A Rader, Biotechnology Information Institute, USA</td>
</tr>
<tr>
<td>James Harris III</td>
<td>James Harris III, Healthcare Economics LLC, USA</td>
</tr>
<tr>
<td>Lisa V Mueller</td>
<td>Lisa V Mueller, Michael Best &amp; Friedrich LLP, USA</td>
</tr>
<tr>
<td>Denise M Kettelberger</td>
<td>Denise M Kettelberger, Sunstein Kann Murphy &amp; Timbers LLP, USA</td>
</tr>
<tr>
<td>Candida Frataazzi</td>
<td>Candida Frataazzi, BBCR Consulting, USA</td>
</tr>
<tr>
<td>Kerisha A Bowen</td>
<td>Kerisha A Bowen, Dentons US LLC, USA</td>
</tr>
<tr>
<td>Nigel Rulewski</td>
<td>Nigel Rulewski, Quintiles, USA</td>
</tr>
<tr>
<td>Tom Carver</td>
<td>Tom Carver, Wragge Lawrence Graham &amp; Co, UK</td>
</tr>
<tr>
<td>Marcus Mreyen</td>
<td>Marcus Mreyen, Protagen Protein Services, Germany</td>
</tr>
<tr>
<td>Min Zhang</td>
<td>Min Zhang, Fujifilm Diosynth Biotechnologies, U.S.A</td>
</tr>
</tbody>
</table>

Exploring government pricing and reimbursement policy challenges associated with biosimilars

The economic viability of a U.S. biosimilars industry

Challenges and approaches in demonstrating biosimilarity at the physicochemical and biological level

Clearing the path for market entry before the USPTO

Similar biologics in India — legal and regulatory perspective

US biosimilars taking flight: Discussion of the key events and cases shaping the US biosimilar landscape

Biosimilars market access and penetration in the Obama care era — considerations for providers, payers, prescribers and patients

AVX-470, an Orally-Delivered GI-Targeted anti-TNF Biobetter

Challenges of the recombinant pharmaceutical biosimilar proteins expression and enhanced refolded recovery from E.coli

Emerging biosimilar in therapeutics: Where we are and what is future?

Day 2   October 27, 2015

**Keynote Forum**

<table>
<thead>
<tr>
<th>Sarfaraz K Niazi</th>
<th>Sarfaraz K Niazi, Therapeutic Proteins International, USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angela Furlanetto</td>
<td>Angela Furlanetto, Dimock Stratton LLP, Canada</td>
</tr>
</tbody>
</table>

Impact of the biosimilars pipeline and nomenclature on market development

Evolution of the global biosimilars market: Lessons learned

Biosimilars: Is the risk worth the reward

Biosimilar Companies and Market Development Worldwide

Patent eligibility challenges to biologics under America Invents Act (AIA) and Myriad

Cost- Effective clinical trial design to detect immunogenicity and efficacy differences between biosimilar and innovator product.

Janssen Biotech V. Celltrion: The balance between the BPCIA and litigation

Issues in the clinical development of the first wave of biosimilars

Supplementary protection certificates (SPCs) in Europe — What is the ‘basic patent’ and what is the ‘product’?

CMC consideration for biosimilar drug development and manufacturing process

Overcome challenges to manufacture of biosimilars through media/feed screening and cell culture process optimization
Erbilut biosimilar
Alan L Epstein, USC Keck School Of Medicine, USA
Production of biosimilar MAbs in transgenic animals– Opportunities and challenges
Roman T Drews, LFB, USA

Poster Presentation
Identification and quantification of flavonoids and their glycosides for quality assessment of Terminalia species applying liquid chromatography hyphenated with mass spectrometric techniques
Awantika Singh, Central Drug Research Institute, India
Patients Satisfaction on Antiretroviral Therapy Monitoring Laboratory Services in public Hospitals, Addis Ababa, Ethiopia.
Tedla Mindaye, Addis Ababa University, Ethiopia
Improving injection force of high viscous drugs by a unique, commercially available needle created by using tapered technology
Mitsuru Takahashi, Terumo Medical Corporation, USA
Structural Modification of the Alpha-helical Antimicrobial Brevinin-2 Related Peptide – A Comparison Study of Biosimilars
Siqin Liu, Queen's University Belfast, UK
Ultra performance liquid chromatography mass spectrometric analysis for rapid quantitation of isoquinoline alkaloids in Thalictrum reniforme
Vikas Bajpai, Central Drug Research Institute, India
Cold active endo-glucanase from Antarctic Yeast, Glaciozyma antarctica PI12; expression and characterisation
Salimeh Mohammadi, University Kebangsaan Malaysia, Malaysia

Day 3 October 28, 2015
Workshop on A review of the how state regulators are dealing with biosimilars. a case study of the Maryland policy debate and legislation
Gene M Ransom III, University of Maryland and University of Baltimore School of Law, USA
Safety and biosimilarity of ior®EPOCIM compared to Eprex® based on toxicologic, pharmacodynamic and pharmacokinetic studies in the Sprague-Dawley rat
Gordon T Bolger, Nucro-Technics, Canada
Prevention potency of soaps and disinfectants on Vancomycin resistant Enterococcus faecalis infection
Adetunji Olawale, Osun State Polytechnic, Nigeria
Bioanalytical challenges of biosimilar development; making you wish you had a mirror to put in front of the innovator drug
Afshin Safavi, BioAgilytix, USA
Protein binding drug-drug interaction
Mariana Babayeva, Touro College of Pharmacy, USA
The characterisation of biosimilar mAbs using biologically relevant and sensitive ADCC methodologies
Andy Upsall, BioOutsorce, UK
Development of a biosimilar CMC strategy for the identification of critical quality attributes
Samantha Little, Covance Laboratories, UK
Characterization of Glatiramer acetate C-terminal heterogeneity
Mario DiPaola, Bluestream Lab., USA

Closing & Award ceremony
Day 1                October 27, 2014

Keynote Forum

| Title: A double blind, phase 1, randomized, parallel-group, single dose, 2 arm, biosimilar study, of a “New Biologic” and “Comparator”, intravenously administered to healthy subjects |
| Title: Biosimilar regulations in the ASEAN |
| Title: Challenges in demonstrating biosimilarity and interchangeability of biosimilar products |
| Title: Comparison of US/EU biosimilar guidelines |
| Title: Challenges and its resolutions in the conduct of biosimilars clinical development |
| Title: Being-similar: From benchside to bedside |
| Title: Quality attributes of biologic products and standard setting process – USP perspective |
| Title: Emerging trends and biosimilars regulation in India |
| Title: Emerging trends in biosimilars and biologics |
| Title: Potential value of biosimilars- will biosimilars be cost effective compared to the branded equivalents? |
| Title: Can excluding pharmaceuticals from patenting will lead to cost effective and quality drugs/biosimilars? |

Workshop

| Title: BCS: A scientific and regulatory tool in drug development process |
| Title: Bioavailability enhancement techniques for BCS Class II and Class IV drugs |

Symposium

| Title: Biosimilars and their prospective future in the market |

Day 2                October 28, 2014

Keynote Forum

| Title: Biological and functional characterization of anti-TNFα biosimilar drugs |
| Title: Evaluation of immunogenicity in biotherapeutics |
| Title: Commercial opportunities in biosimilars |
| Title: Plant derived cyclopolyptides: Targets for drug discovery |
| Title: Risk assessment: A pragmatic approach to develop biosimilars |
| Title: Successful conduct of clinical trials to prove biosimilarity by defining a best fit outsourcing strategy |
| Title: Intas–Merck Millipore: Partnership in biosimilars development strategy for emerging markets |
| Title: Enzyme engineering: An innovative way to manage the economics of biosimilars- Polyclone case study |
| Title: Roadmap of stability studies for biosimilar product development |
| Title: Future of next generation biosimilars |

Title: A double blind, phase 1, randomized, parallel-group, single dose, 2 arm, biosimilar study, of a “New Biologic” and “Comparator”, intravenously administered to healthy subjects

Krishna Menon, Cellceutix Corporation, USA

Shivraj Dasari, SLS Cell Core Technologies Pvt. Ltd., India

Rodeina Challand, PRA Health Sciences, UK

Kamali Chance, Quintiles Inc., USA

Chirag Shah, Cliantha Research Ltd., India

Manish Mahajan, Lupin Ltd., India

Ranjak Chakraborty, United States Pharmacopeia India Pvt. Ltd., India

Chirag Shah, Ciatheansa Research Ltd., India

Surendra J Chavan, Quantimmune Solutions Pvt. Ltd., India

Rajiv Dahiya, Association of Pharmacy Professionals, India

Harish Shandilya, INTAS Biopharmaceuticals Ltd., India

Shabana Khan, Ecron Acunova, India

Shilpa Bhilegaonkar, PES’s Rajaram & Tarabai Bandekar College of Pharmacy, India

Daniel Galbraith, BioOutsource Ltd., UK

Surendra J Chavan, Quantimmune Solutions Pvt. Ltd., India

Surendra J Chavan, Quantimmune Solutions Pvt. Ltd., India

Daniel Galbraith, BioOutsource Ltd., UK

Rajiv Dahiya, Association of Pharmacy Professionals, India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India

INTAS Biopharmaceuticals Ltd., India
Title: Clinical development of biosimilars: Overcoming challenges  
Charu Manaktala, Quintiles Inc., India  
Title: Challenges faced in the development of biosimilars  
Hima Bindu Gujjarlamudi, Rajiv Gandhi Institute of Medical Sciences (RIMS), India  
Title: Clinical trials of biosimilars in developing nations: obstacles and opportunities  
N Srinivas, Malla Reddy Institute of Pharmaceutical Sciences, India  
Title: Best practices for high concentration ultrafiltration applications  
Subhasis Banerjee, Merck Millipore, India  
Title: Bioanalytical strategy for biosimilars: Recommended steps for establishment of comparability  
Aparna Kasinath, Clinigene International Ltd., India  
Title: Understanding osteomyelitis and its solution through cost effective biomaterial based strategies  
Samit Kumar Nandi, West Bengal University of Animal and Fishery Sciences, India  
Title: Virus filtration for biosimilar manufacturing: from needs to solutions  
Tathagata Ray, Merck Millipore, India  
Title: An alternate approach for sialic acid estimation in erythropoietin by HPAEC-PAD method  
R Jayachandran, United States Pharmacopeia India Pvt. Ltd., India  
Title: Analytical biosimilarity: Strategies and challenges  
Shalini Sharma, Intas Pharmaceuticals Ltd., India  
Title: Alternate approaches addressing variability in ADCC assay  
Prabhavathy Munagala, United States Pharmacopeia India Pvt. Ltd., India

Presentations @ Hall 4

Day 3 October 29, 2014

Title: Biosimilars in the United States—Update on FDA implementation and other current issues  
James C Shehan, Hyman, Phelps & McNamara, USA  
Title: The positive role of intellectual property in the creation of cost effective and affordable biosimilars  
Mohan Dewan, R.K. Dewan & Co., India  
Title: IP checklist for similar biologics  
Mita Sheikh, Krishna & Saurastri Associates, India  
Title: Patent issues in biopharmaceutical industry  
Vijay Kumar, BioBridge Healthcare Solutions Pvt. Ltd., India  
Title: The exclusions from patentability and especially the rationale for medical use patents  
Dieter Tzschoppe, European Patent Office, Germany

Coffee Break 10:40-10:55 @ Hall 4

Title: Patenting of biosimilars in India and related issues  
Vijay Kumar Makyam, IP Markets, India  
Title: Compulsory licensing: A delicate balance between biosimilars and innovations  
Poongothai A R, IP Markets, India  
Title: Challenges for biosimilar generics  
Vivek Kashyap, Lex Orbis IP Practice, India  
Title: Preparing for U.S. market entry—strategy considerations in view of BPCIA and AIA  
Renita S Rathinam, Sughrue Mion PLLC, USA

Title: Biosimilars: Globalization of biosimilars  
Ravi R Ghanghas, Govt. Medical College, India  
Title: A next generation sequencing approach drives target personalized therapy of acute myeloid leukemia  
Giovanni Martinelli, Bologna University School of Medicine, Italy  
Title: Host cell protein and other impurity clearance assays for biosimilar development  
Arumugam Muruganandam, Affigenix Biosolutions Pvt. Ltd., India

Title: Safety concerns related to global biosimilars drug development  
Nigel Rulewski, Quintiles Inc., USA  
Title: Pharmacovigilance of biosimilars: Challenges & possible solutions  
J Vijay Venkatraman, Oviya MedSafe, India  
Title: Role of pharma industries in the improvement of pharmacovigilance system  
Kamlesh Patel, Abbott HealthCare Pvt. Ltd., India  
Title: Synergism of ‘nutraceutical’ and ‘pharmaceutical’ for safety  
Ekta K Kalra, Ekta K Kalra Writing Company, India  
Title: The key roles & responsibilities of pharmacists in biosimilars development  
N Srinivas, Malla Reddy Institute of Pharmaceutical Sciences, India

Panel Discussion: 15:40-15:45

Young Researcher Forum

Title: Bimodal gastroretentive drug delivery systems of lamotrigine: Formulation and evaluation  
Rajasekhar Reddy Poonuru, St. Peter’s Institute of Pharmaceutical Sciences, India  
Title: Dissolution testing of nicotinamide cocrystals of a model BCS Class-II drug  
Kale Mohana Raghava Srivalli, IIT (BHU), India
Title: Medication usage and nutritional status in hemodialysis
S Chan Mubeena, Sri Padmavathi Mahila Viswavidyalayam, India

Title: Combined approach of biosimilar trastuzumab monoclonal antibody with nanoparticles targeted to prostate tumor cells
Dubey Satendra Kumar, JSS University, India

Title: Effect of lipid digestion media on the fate of drug in lipid based nanoemulsion
R Suresh Kumar, JSS University, India

Title: Design and synthesis of some novel antibacterial agents targeting Gyrase B and Par E
Janarthanan T, JSS University, India

Title: The quest for cost effective treatment in rheumatoid arthritis: Are biosimilars the right choice?
Phani Kishore Thimmamaraju, Phamax Market Access Solutions, India

Title: In vivo characterization of snail extract loaded marine biomaterials in bone regeneration
Piyali Das, West Bengal University of Animal and Fishery Sciences, India

Title: Effect of curcumin in celecoxib and streptozotocin induced experimental dementia of Alzheimer disease in mice
Ahssas Goyal, DGLA University, India

Title: Recombinant version of streptokinase: An overview
Alice Jaya Pradha Cheekurthy, Acharya Nagarjuna University, India

Title: Demonstration of multivariate data analysis for the development of Boswellia serrata plant extracts containing nanoemulsion
Mukesh Gohel, Anand Pharmacy College, India

Title: Development and evaluation of digestive enzyme formulations
Chaudhari Nilesh B, Sandip Institute of Pharmaceutical Sciences, India

Title: Serotonin storm- A drug induced syndrome
Lilli Sailaja G, Doctor of Pharmacy Association, India

Title: Survey of US certified diabetes educators (CDEs) suggests high interest in future use of biosimilar insulin due to cost savings
Jessica Dong, Close Concerns Inc., USA

Title: The challenge of tuberculosis to the global public health care: A clinical pharmacist perspective
Khadeer Ahmed Ghori, Doctor of Pharmacy Association, India

Title: The Indian pharmaceutical industries should support dichloroacetate (DCA): A new potential metabolic-targeting drug available at low price for cancer treatment
M Manasa Rekha, Doctor of Pharmacy Association, India

Title: The omega-3 fatty acids serves as alternate safe new pharmacological treatment for cardio vascular diseases which effectively decreases the mortality
M Navya Sree, Doctor of Pharmacy Association, India

Title: Investigation of actual chemical constituents and anti-inflammatory activity of Arka leaves extracts
Mohammed Rageeb Mohammed Usman, Smt. Sharadchandrika Suresh Patil College of Pharmacy, India

Title: Drug discovery: Though chemi-bioinformatics-from system to market
M Murali Mohan Gutti, JNTU, India

Title: Antihypertensive effect of leaves of Tephrosia purpurea Linn. on isolated frog heart
Sufiyan Ahmad, Gangamai College of Pharmacy, India

Title: Development of validated analytical method for risperidone in pharmaceutical solid dosage form by HPTLC
Sunil Singh, Mewar University, India

Title: Synthesis and pharmacological screening of some benzimidazole derivatives
Sunila T Patil, P.S.G.V.P.M’s College of Pharmacy, India

Title: Acceptance of biosimilar products in the treatment of rheumatoid arthritis
Narendra Kumar Vemulapalli, Doctor of Pharmacy Association, India

Title: Monitoring adverse drug reaction of various pharmaceutical products in rural population of South India
Stefin Mary Mathew, Doctor of Pharmacy Association, India

Title: Development and validation of RP-HPLC method for simultaneous estimation of cefixime and cloxacillin from tablet dosage-form
Wankhede Ajit R, Sandip Institute of Pharmaceutical Sciences, India

Title: Risk of stroke in smokers
B Jyothi, Doctor of Pharmacy Association, India

Title: Over the counter drugs - Advantages and risks of self-management of OTC drugs in older adult patients
B Neelima, Doctor of Pharmacy Association, India

Title: Neuroleptic malignant syndrome - A neuroleptic induced syndrome
K V Jagadeesh, Doctor of Pharmacy Association, India

Title: Evaluation of behavioural studies of Linum usitatissimum
R Naga Kishore, Geethanjali College of Pharmacy, India

Title: Cefpodoxime proxetil gastroretentive effervescent floating tablets by using various hydrophilic polymers
M Naga Ganesh, Geethanjali College of Pharmacy, India
Title: Development and validation of UV- spectrophotometric simultaneous equation method for simvastatin and ezetimibe in tablet formulation
Murtadak Sagar N, Sandip Institute of Pharmaceutical Sciences, India

Title: Bioanalysis of riluzole in human plasma by a sensitive LC-MS/MS method and its application to a pharmacokinetic study in South Indian subjects
Anjaneyulu Narapusetti, Geethanjali College of Pharmacy, India

Title: Pharmaceutical care program educate patient on quality of life (QOL) in type2 diabetes mellitus in Dhule
Tabrez Mujawar, R. C. Patel Institute of Pharmaceutical Education & Research, India

Title: Extraction and characterization of gum from Lepidium sativum Linn. and Cordia dichotoma Linn. for its film forming properties and studies about release characteristic of these films
Vaibhav M Darvhekar, P. Wadvani College of Pharmacy, India

Title: Biosimilars-destination in India
J Sadhana Reddy, Anurag Group of Institution, India

Title: Liquisolid technique for dissolution enhancement of hormones belonging to BCS Class II
Sameer Nadaf, Bharati Vidyapeeth College of Pharmacy, India

Title: New visible spectrophotometric methods for the assay of spiramycin
Karteek Rao Amperayani, GITAM University, India

Title: Pharmacognostic studies, bianthraquinones and spermidine alkaloid from Cassia floribunda
Podila Venu, The University of Greenwich, UK

Title: Search for effective antimycotic agents against Microsporum gypseum from 61 ethno medicinal plants of Hyderabad Karnataka region, India
Shivakumar Singh P, Gulbarga University, India

Title: Current problems and future aspects of pharmacovigilance in India
Pragnya Devi U, Doctor of Pharmacy Association, India

Title: Synthesis and biological activity of a cyclic hexapeptide from Dianthus superbus
Suresh Beniwal, Kurukshetra University, India

Title: Potential role of pharma-industries in addressing the challenges in pharmacovigilence: Practice changes & outcome trends
Malavika Maheswari K, Doctor of Pharmacy Association, India

Title: Anti-cancer biosimilars from natural products
P V Lalith, Gurunanak Institute of Pharmacy, India

Title: Assessment of knowledge, adherence and attitude of patients towards tuberculosis, its medications and effect of counselling in a medical college outpatient clinic
Syeda Sumayya Siraj, Deccan School of Pharmacy, India

Title: Cost-effectiveness and pharmacoeconomic analysis of combined inhaled corticosteroids and brochodilators for severe and very severe COPD patients and health related quality of Life of COPD patients in a teaching hospital
Mohammed Altaf, Deccan School of Pharmacy, India

Title: Synthesis and antimicrobial screening of 1, 2, 4 H-triazole derivatives
Neha Yadav, VNS Faculty of Pharmacy, India

Title: Agrobacterium-mediated genetic transformation of tobacco cells and annexin gene cloning using pTZ57R/T vector
Jithender D, Osmania University, India